In a recent government meeting, officials highlighted the alarming trend of increasing consolidation across U.S. industries, with over 75% becoming more concentrated since the late 1990s. This consolidation has led to significant economic implications, including fewer choices for consumers, higher prices, and diminished innovation. Since 2008, American firms have engaged in over $10 trillion in acquisitions, affecting various sectors from ticketing to food production.

The meeting underscored the vulnerabilities created by this consolidation, particularly in supply chains, which can jeopardize both economic stability and national security. For instance, the reliance on a single facility for the production of generic drug ingredients has left the U.S. healthcare system exposed to shortages. The FDA estimates that generic drugs saved Americans over $53 billion from 2018 to 2020, yet one-third of the active ingredients are produced in a single overseas facility, with only 14% manufactured domestically.

The discussion also referenced the aftermath of Hurricane Maria in 2017, which caused a shortage of IV bags due to the consolidation of production in Puerto Rico. Additionally, a recent cyberattack on Change Healthcare, a major player in the healthcare supply chain, disrupted over 101,000 electronic systems, affecting payment processes for healthcare providers and risking the viability of small practices.

The meeting concluded with a call to action, emphasizing the need for a diverse and resilient economy that supports both small businesses and larger corporations. The passage of the CHIPS and Science Act was highlighted as a critical step toward increasing domestic semiconductor production, aiming to reduce reliance on foreign manufacturing and enhance supply chain security. The officials urged a shift away from market dominance by a few giants, advocating for competitive markets that foster growth and innovation.